Sponsored Sessions
(Please note this programme is subject to change)
Meet the Expert
Functional Regurgitation (FRM) in Patients With Heart Failure: Unmet Needs and Future Perspectives
Chair: Stefan Anker
Welcome - Stefan Anker
FMR in Heart Failure: Two Phenotypes (Ventricular and Atrial FMR), One Unmet Need - Alper Öner
Future Perspectives: Indirect Annuloplasty With Carillon in Real-World Practice - Peter Nordbeck
Discussion: Tailoring Treatment: Which Patient, Which Phenotype, Which Intervention?
Close - Stefan Anker
Supported by an unrestricted educational grant from Cardiac Dimensions
Symposium
Symposium: Implementing 2026 Heart Failure Guidelines Management of Iron Deficiency Along the Patient’s Journey
Chair: Stefan Anker
-
Welcome - Stefan Anker
-
Guidelines for the Management of Iron Deficiency in Heart Failure – Definition, Screening, and Treatment -Daniela Tomasoni
-
Benefits of Intravenous Iron Therapy in Patients With HFrEF - Insights From an Individual-Patient-Data Meta-Analysis – John Cleland
-
Management of Iron Deficiency Along the Patient’s Journey – Translating Evidence Into Clinical Practice – Gianluigi Savarese
-
Panel Discussion and Q&A - All
-
Close - Stefan Anker
Supported by an unrestricted educational grant from CSL Vifor
Meet the Expert
Implementing SGLT2 Inhibitors Across The Heart Failure Continuum: From Prevention to Advanced Disease
Welcome
Foundational Therapy Across the HF Continuum: SGLT2 Inhibitors From Prevention (Stages A–B) to Established and Advanced Heart Failure (Stages C–D) - Javed Butler
From Evidence to Implementation: Start Early, Combine Rapdly, Persist - Biykem Bozkurt
Panel Discussion
Close
Supported by an unrestricted educational grant from Boehringer Ingelheim
Meet the Expert
REPLAY: Functional Regurgitation (FRM) in Patients With Heart Failure: Unmet Needs and Future Perspectives
Chair: Stefan Anker
-
Welcome - Stefan Anker
-
FMR in Heart Failure: Two Phenotypes (Ventricular and Atrial FMR), One Unmet Need - Alper Öner
-
Future Perspectives: Indirect Annuloplasty With Carillon in Real-World Practice - Peter Nordbeck
-
Discussion: Tailoring Treatment: Which Patient, Which Phenotype, Which Intervention?
-
Close - Stefan Anker
Supported by an unrestricted educational grant from Cardiac Dimensions
Meet the Expert
REPLAY: Implementing SGLT2 Inhibitors Across The Heart Failure Continuum: From Prevention to Advanced Disease
Welcome
Foundational Therapy Across the HF Continuum: SGLT2 Inhibitors From Prevention (Stages A–B) to Established and Advanced Heart Failure (Stages C–D) - Javed Butler
From Evidence to Implementation: Start Early, Combine Rapdly, Persist - Biykem Bozkurt
Panel Discussion
Close
Supported by an unrestricted educational grant from Boehringer Ingelheim
Meet the Expert
Non-Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Which Patients, When to Initiate and How to Follow-Up?
-
Welcome - Maja Cikes
-
Which Heart Failure Patient Benefit From nsMRAs? - Muthiah Vaduganathan
-
How to Initiate and Follow-up HF Patients on nsMRAs? - Maja Cikes
-
Panel Discussion and Q&A
-
Close - Muthiah Vaduganathan
Supported by an unrestricted educational grant from Bayer
Meet the Expert
Two Numbers, One Foundational Therapy: eGFR, UACR and SGLT2 Inhibitors Patients with HF and CKD
-
Welcome
-
Two Numbers That Matter: Screening for CKD With eGFR and UACR in Patients With Heart Failure - James Burton
-
One Foundational Therapy: SGLT2 Inhibitors Across the eGFR Spectrum - From EMPA-KIDNEY to Integrated Cardiorenal Care - Shelley Zieroth
-
Panel Discussion and Q&A
-
Close
Supported by an unrestricted educational grant from Boehringer Ingelheim
Sponsors




If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com
About Translational Medicine Academy
Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.
Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.
For more information on TMA, please visit www.tmacademy.org.
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community
We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.
We bring medical knowledge to life
From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.
Our work is underpinned by 3 core principles:
- We build on the best science
- We work hands-on with our community
- We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.
For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com
